Guselkumab Versus Risankizumab for Ulcerative Colitis: Real-World Comparison of Post-Induction Outcomes. Dalal RS, Silvestri ME, Kwaning KM, Carlin AD, et al. Clin Gastroenterol Hepatol 2026 Sep 23:S1542-3565(26)00721.

Read + Share

Amedeo Smart

Independent Medical Education

Dalal RS, Silvestri ME, Kwaning KM, Carlin AD, et al. Guselkumab Versus Risankizumab for Ulcerative Colitis: Real-World Comparison of Post-Induction Outcomes. Clin Gastroenterol Hepatol 2026 Sep 23:S1542-3565(26)00721.
PMID: 42777856